Celerion, a Lincoln, NE-based provider of clinical study solutions to pharmaceutical and biotechnology clients conducting early clinical research, has announced the successful recapitalization of its business through investment by MTS Health Investors, LLC, a New York-based healthcare private equity firm.
MTS has partnered with management and will provide capital to support future growth.
Led by Susan Thornton PhD, President and CEO, Celerion conducts and analyzes First-in-Human, clinical Proof-of-Concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. It provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development.
Regulatory, drug development and program management complement its service offerings.
With operations throughout North America, Europe and Asia, the company serves clients through its global network of owned facilities with a focus on Applied Translational Medicine to support early drug development decisions.